XML 38 R27.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables) | 9 Months Ended
--- | ---
Mar. 31, 2024
Notes Tables |
Schedule of the Consolidated Changes in Equity | ​ Consolidated Changes in Equity (amounts in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Bio-Techne Shareholders |  | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Accumulated | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Additional | ​ | ​ | ​ | ​ | Other | ​ | ​ | ​
​ | ​ | Common Stock | ​ | Paid-in | ​ | Retained | ​ | Comprehensive | ​ | ​
​ | ​ | Shares | ​ | Amount | ​ | Capital | ​ | Earnings | ​ | Income(Loss) | ​ | Total
Balances at June 30, 2023 |  | 157,642 | ​ | $ | 1,576 | ​ | $ | 721,543 | ​ | $ | 1,309,461 | ​ | $ | (66,064) | ​ | $ | 1,966,516
Net earnings |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ |  | 50,993 | ​ |  | ​ | ​ |  | 50,993
Other comprehensive income (loss) |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | (11,952) | ​ |  | (11,952)
Common stock issued for exercise of options |  | 633 | ​ |  | 6 | ​ |  | 12,877 | ​ |  | (15,460) | ​ |  | ​ | ​ |  | (2,577)
Common stock issued for restricted stock awards |  | 47 | ​ | ​ | 1 | ​ |  | 0 | ​ |  | (4,768) | ​ |  | ​ | ​ |  | (4,767)
Cash dividends |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ |  | (12,654) | ​ |  | ​ | ​ |  | (12,654)
Stock-based compensation expense |  | ​ | ​ |  | ​ | ​ |  | 9,981 | ​ |  | ​ | ​ |  | ​ | ​ |  | 9,981
Common stock issued to employee stock purchase plan |  | 33 | ​ | ​ | 1 | ​ |  | 2,093 | ​ |  | ​ | ​ |  | ​ | ​ |  | 2,094
Employee stock purchase plan expense | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 112 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 112
Balances at September 30, 2023 |  | 158,355 | ​ | $ | 1,584 | ​ | $ | 746,606 | ​ | $ | 1,327,572 | ​ | $ | (78,016) | ​ | $ | 1,997,746
Net earnings |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 27,465 | ​ | ​ | ​ | ​ |  | 27,465
Other comprehensive income (loss) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 14,355 | ​ | ​ | 14,355
Share repurchases |  | (1,397) | ​ | ​ | (14) | ​ | ​ | ​ | ​ | ​ | (80,028) | ​ | ​ | ​ | ​ |  | (80,042)
Common stock issued for exercise of options |  | 157 | ​ | ​ | 1 | ​ | ​ | 4,914 | ​ | ​ | (1,074) | ​ | ​ | ​ | ​ |  | 3,841
Common stock issued for restricted stock awards |  | 27 | ​ | ​ | 0 | ​ | ​ | 0 | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | 0
Cash dividends |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (12,559) | ​ | ​ | ​ | ​ |  | (12,559)
Stock-based compensation expense |  | ​ | ​ | ​ | ​ | ​ | ​ | 12,413 | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | 12,413
Employee stock purchase plan expense | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 340 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 340
Balances at December 31, 2023 |  | 157,142 | ​ | $ | 1,571 | ​ | $ | 764,273 | ​ | $ | 1,261,376 | ​ | $ | (63,661) | ​ | $ | 1,963,559
Net earnings | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 49,059 | ​ | ​ | ​ | ​ | ​ | 49,059
Other comprehensive income (loss) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (11,646) | ​ | ​ | (11,646)
Common stock issued for exercise of options | ​ | 372 | ​ | ​ | 4 | ​ | ​ | 15,761 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 15,765
Common stock issued for restricted stock awards | ​ | 4 | ​ | ​ | 0 | ​ | ​ | 0 | ​ | ​ | (168) | ​ | ​ | ​ | ​ | ​ | (168)
Cash dividends | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (12,579) | ​ | ​ | ​ | ​ | ​ | (12,579)
Stock-based compensation expense | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 8,053 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 8,053
Common stock issued to employee stock purchase plan | ​ | 36 | ​ | ​ | 1 | ​ | ​ | 2,251 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 2,252
Employee stock purchase plan expense | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 80 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 80
Balances at March 31, 2024 |  | 157,554 | ​ | $ | 1,576 | ​ | $ | 790,418 | ​ | $ | 1,297,688 | ​ | $ | (75,307) | ​ | $ | 2,014,375
​ ​ ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Bio-Techne Shareholders |  | ​ | ​ |  |  | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Accumulated | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Additional | ​ | ​ | ​ | ​ | Other | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Common Stock | ​ | Paid-in | ​ | Retained | ​ | Comprehensive | ​ | Noncontrolling | ​ | ​ | ​
​ | ​ | Shares | ​ | Amount | ​ | Capital | ​ | Earnings | ​ | Income(Loss) | ​ | Interest | ​ | Total
Balances at June 30, 2022 |  | 156,644 | ​ | $ | 1,566 | ​ | $ | 652,467 | ​ | $ | 1,122,937 | ​ | $ | (75,200) | ​ | $ | (759) | ​ | $ | 1,701,011
Net earnings |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ |  | 89,555 | ​ |  | ​ | ​ |  | 179 | ​ |  | 89,734
Other comprehensive income (loss) |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | (16,762) | ​ |  | ​ | ​ |  | (16,762)
Reclassification of cumulative translation adjustment for Eminence to non-operating income | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 152 | ​ | ​ | (33) | ​ | ​ | 119
Elimination of noncontrolling equity interest from sale of Eminence |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | 613 | ​ |  | 613
Share repurchases |  | (222) | ​ |  | (2) | ​ |  | ​ | ​ |  | (19,560) | ​ |  | ​ | ​ |  | ​ | ​ |  | (19,562)
Common stock issued for exercise of options |  | 425 | ​ |  | 5 | ​ |  | 9,418 | ​ |  | (11,428) | ​ |  | ​ | ​ |  | ​ | ​ |  | (2,005)
Common stock issued for restricted stock awards |  | 45 | ​ | ​ | 0 | ​ |  | 0 | ​ |  | (6,427) | ​ |  | ​ | ​ |  | ​ | ​ |  | (6,427)
Cash dividends |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ |  | (12,545) | ​ |  | ​ | ​ |  | ​ | ​ |  | (12,545)
Stock-based compensation expense |  | ​ | ​ |  | ​ | ​ |  | 14,364 | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | 14,364
Common stock issued to employee stock purchase plan |  | 36 | ​ | ​ | 0 | ​ |  | 2,517 | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | 2,517
Employee stock purchase plan expense | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 97 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 97
Balances at September 30, 2022 |  | 156,928 | ​ | $ | 1,569 | ​ | $ | 678,863 | ​ | $ | 1,162,532 | ​ | $ | (91,810) | ​ | $ | — | ​ | $ | 1,751,154
Net earnings |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 50,005 | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | 50,005
Other comprehensive income (loss) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 16,685 | ​ | ​ | ​ | ​ | ​ | 16,685
Common stock issued for exercise of options |  | 155 | ​ | ​ | 1 | ​ | ​ | 5,074 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | 5,075
Common stock issued for restricted stock awards |  | 11 | ​ | ​ | 1 | ​ | ​ | 1 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | 2
Cash dividends |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (12,561) | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | (12,561)
Stock-based compensation expense |  | ​ | ​ | ​ | ​ | ​ | ​ | 16,413 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | 16,413
Employee stock purchase plan expense | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 333 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 333
Balances at December 31, 2022 |  | 157,094 | ​ | $ | 1,571 | ​ | $ | 700,684 | ​ | $ | 1,199,976 | ​ | $ | (75,125) | ​ | $ | — | ​ | $ | 1,827,106
Net earnings |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 70,218 | ​ |  | ​ | ​ |  | ​ | ​ |  | 70,218
Other comprehensive income (loss) |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | 1,574 | ​ |  | ​ | ​ |  | 1,574
Share repurchases | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | —
Common stock issued for exercise of options |  | 201 | ​ |  | 2 | ​ |  | 1,871 | ​ |  | (10,733) | ​ |  | ​ | ​ | ​ | ​ | ​ |  | (8,860)
Common stock issued for restricted stock awards |  | 6 | ​ |  | 0 | ​ |  | 0 | ​ |  | (267) | ​ |  | ​ | ​ | ​ | ​ | ​ |  | (267)
Cash dividends |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ |  | (12,582) | ​ |  | ​ | ​ | ​ | ​ | ​ |  | (12,582)
Stock-based compensation expense |  | ​ | ​ | ​ | ​ | ​ |  | 9,995 | ​ |  | ​ | ​ |  | ​ | ​ | ​ | ​ | ​ |  | 9,995
Common stock issued to employee stock purchase plan | ​ | 38 | ​ | ​ | 0 | ​ | ​ | 2,389 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 2,389
Employee stock purchase plan expense |  | ​ | ​ | ​ | ​ | ​ |  | 113 | ​ |  | ​ | ​ |  | ​ | ​ | ​ | ​ | ​ |  | 113
Balances at March 31, 2023 |  | 157,339 | ​ | $ | 1,573 | ​ | $ | 715,052 | ​ | $ | 1,246,612 | ​ | $ | (73,551) | ​ | $ | — | ​ | $ | 1,889,686
Schedule of changes in Accumulated Other Comprehensive Income (Loss) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Three months ended March 31, 2024 (in thousands): | ​ | Unrealized | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Gains | ​ | Foreign | ​ | ​ | ​
​ | ​ | (Losses) on | ​ | Currency | ​ | ​ | ​
​ | ​ | Derivative | ​ | Translation | ​ | ​ | ​
​ |  | Instruments |  | Adjustments |  | Total
Balance as of December 31, 2023, net of tax: | ​ | $ | 8,842 | ​ | $ | (72,503) | ​ | $ | (63,661)
Other comprehensive income (loss), before tax: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amounts before reclassifications | ​ | ​ | (1,626) | ​ | ​ | (12,620) | ​ | ​ | (14,246)
Amounts reclassified out | ​ | ​ | 2,570 | ​ | ​ | 837 | ​ | ​ | 3,407
Total other comprehensive income (loss), before tax | ​ | ​ | 944 | ​ | ​ | (11,783) | ​ | ​ | (10,839)
Tax (expense)/benefit | ​ | ​ | (609) | ​ | ​ | (198) | ​ | ​ | (807)
Total other comprehensive income (loss), net of tax | ​ |  | 335 | ​ | ​ | (11,981) | ​ | ​ | (11,646)
Balance as of March 31, 2024, net of tax | ​ | $ | 9,177 | ​ | $ | (84,484) | ​ | $ | (75,307)
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Three months ended March 31, 2023 (in thousands): | ​ | Unrealized | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Gains | ​ | Foreign | ​ | ​ | ​
​ | ​ | (Losses) on | ​ | Currency | ​ | ​ | ​
​ | ​ | Derivative | ​ | Translation | ​ | ​ | ​
​ |  | Instruments |  | Adjustments |  | Total
Balance as of December 31, 2022, attributable to Bio-Techne, net of tax: | ​ | $ | 12,079 | ​ | $ | (87,204) | ​ | $ | (75,125)
Other comprehensive income (loss), before tax: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amounts before reclassifications, attributable to Bio-Techne | ​ | ​ | (3,105) | ​ | ​ | 3,282 | ​ | ​ | 177
Amounts reclassified out | ​ | ​ | 1,826 | ​ | ​ | — | ​ | ​ | 1,826
Total other comprehensive income (loss), before tax | ​ | ​ | (1,279) | ​ | ​ | 3,282 | ​ | ​ | 2,003
Tax (expense)/benefit | ​ | ​ | (429) | ​ | ​ | — | ​ | ​ | (429)
Total other comprehensive income (loss), net of tax | ​ |  | (1,708) | ​ | ​ | 3,282 | ​ | ​ | 1,574
Balance as of March 31, 2023, net of tax | ​ | $ | 10,371 | ​ | $ | (83,922) | ​ | $ | (73,551)
​ ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Nine months ended March 31, 2024 (in thousands): | ​ | Unrealized | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Gains | ​ | Foreign | ​ | ​ | ​
​ | ​ | (Losses) on | ​ | Currency | ​ | ​ | ​
​ | ​ | Derivative | ​ | Translation | ​ | ​ | ​
​ |  | Instruments |  | Adjustments |  | Total
Balance as of June 30, 2023, net of tax: | ​ | $ | 12,862 | ​ | $ | (78,926) | ​ | $ | (66,064)
Other comprehensive income (loss), before tax: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amounts before reclassifications | ​ | ​ | (9,582) | ​ | ​ | (7,368) | ​ | ​ | (16,950)
Amounts reclassified out | ​ | ​ | 7,729 | ​ | ​ | 2,372 | ​ | ​ | 10,101
Total other comprehensive income (loss), before tax | ​ | ​ | (1,853) | ​ | ​ | (4,996) | ​ | ​ | (6,849)
Tax (expense)/benefit | ​ | ​ | (1,832) | ​ | ​ | (562) | ​ | ​ | (2,394)
Total other comprehensive income (loss), net of tax | ​ |  | (3,685) | ​ | ​ | (5,558) | ​ | ​ | (9,243)
Balance as of March 31, 2024, net of tax(1) | ​ | $ | 9,177 | ​ | $ | (84,484) | ​ | $ | (75,307)
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Nine months ended March 31, 2023 (in thousands): | ​ | Unrealized | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Gains | ​ | Foreign | ​ | ​ | ​
​ | ​ | (Losses) on | ​ | Currency | ​ | ​ | ​
​ | ​ | Derivative | ​ | Translation | ​ | ​ | ​
​ |  | Instruments |  | Adjustments |  | Total
Balance as of June 30, 2022, attributable to Bio-Techne, net of tax: | ​ | $ | 8,069 | ​ | $ | (83,269) | ​ | $ | (75,200)
Other comprehensive income (loss), before tax: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amounts before reclassifications, attributable to Bio-Techne | ​ | ​ | 431 | ​ | ​ | (805) | ​ | ​ | (374)
Amounts reclassified out | ​ | ​ | 2,445 | ​ | ​ | 152 | ​ | ​ | 2,597
Total other comprehensive income (loss), before tax | ​ | ​ | 2,876 | ​ | ​ | (653) | ​ | ​ | 2,223
Tax (expense)/benefit | ​ | ​ | (574) | ​ | ​ | — | ​ | ​ | (574)
Total other comprehensive income (loss), net of tax | ​ |  | 2,302 | ​ | ​ | (653) | ​ | ​ | 1,649
Balance as of March 31, 2023, net of tax(1) | ​ | $ | 10,371 | ​ | $ | (83,922) | ​ | $ | (73,551)
(1) The Company had a net deferred tax liability for its cash flow hedge of $2.9 million and $3.2 million for the nine months ended March 31, 2024 and 2023, respectively,

X
- Definition Tabular disclosure of the components of accumulated other comprehensive income (loss). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20 + Details
Name: | us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration